QNRX:NASDAQ, Quoin Pharmaceuticals, Ltd.
QNRX stock overview
Quoin Pharmaceuticals, Ltd. (QNRX:NASDAQ) closed at $3.28 on November 20, 2026,
down 2.35% on the day.
The stock trades 86.0% below its 52-week high of $23.50
and 3.1% above its 52-week low of $3.18.
Over the past year, it lost 83.3%.
Quoin Pharmaceuticals, Ltd. is part of the Health Care sector.
Key figures
- Price
- $3.28
- Day change
- -2.35%
- Volume
- 11,312
- Average volume
- 542,214
- Market cap
- 15M+
- 52-week range
- $3.18 – $23.50
- 50-day average
- $4.71
- 200-day average
- $5.68
Price action over the past year
In 252 trading sessions since November 20, 2025, QNRX closed higher on 107 days (42%).
Its best day was December 17, 2025 (+24.57%) and its worst was December 5, 2025 (-36.07%).
The stock moved 10% or more in a single session 25 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
QNRX news
-
Nov 6, 2026:
Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
-
Nov 5, 2026:
Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
-
Oct 29, 2026:
Quoin Pharmaceuticals Heads Into Q3 With A Flat Loss Bar And A Stock Near Its Lows
-
Oct 29, 2026:
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
-
Oct 20, 2026:
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
-
Oct 14, 2026:
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
-
Oct 6, 2026:
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
-
Sep 24, 2026:
Four Small-Cap Stocks Report New Developments (CHGA, QNRX, MYSE, LNKS)
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Similar stocks
Find more stocks like QNRX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.